JP2019526270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526270A5 JP2019526270A5 JP2019513999A JP2019513999A JP2019526270A5 JP 2019526270 A5 JP2019526270 A5 JP 2019526270A5 JP 2019513999 A JP2019513999 A JP 2019513999A JP 2019513999 A JP2019513999 A JP 2019513999A JP 2019526270 A5 JP2019526270 A5 JP 2019526270A5
- Authority
- JP
- Japan
- Prior art keywords
- bcr
- nucleic acid
- acid encoding
- primary
- therapeutic cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162584A JP2022189863A (ja) | 2016-09-12 | 2022-10-07 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
| JP2025171949A JP2025188209A (ja) | 2016-09-12 | 2025-10-10 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393512P | 2016-09-12 | 2016-09-12 | |
| US62/393,512 | 2016-09-12 | ||
| PCT/US2017/051182 WO2018049401A1 (en) | 2016-09-12 | 2017-09-12 | Genome edited primary b cell and methods of making and using |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162584A Division JP2022189863A (ja) | 2016-09-12 | 2022-10-07 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526270A JP2019526270A (ja) | 2019-09-19 |
| JP2019526270A5 true JP2019526270A5 (enExample) | 2020-10-22 |
Family
ID=61562180
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513999A Withdrawn JP2019526270A (ja) | 2016-09-12 | 2017-09-12 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
| JP2022162584A Pending JP2022189863A (ja) | 2016-09-12 | 2022-10-07 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
| JP2025171949A Pending JP2025188209A (ja) | 2016-09-12 | 2025-10-10 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162584A Pending JP2022189863A (ja) | 2016-09-12 | 2022-10-07 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
| JP2025171949A Pending JP2025188209A (ja) | 2016-09-12 | 2025-10-10 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220168342A1 (enExample) |
| EP (1) | EP3509606A4 (enExample) |
| JP (3) | JP2019526270A (enExample) |
| CN (1) | CN109843303A (enExample) |
| AU (1) | AU2017322733B2 (enExample) |
| CA (1) | CA3036820A1 (enExample) |
| NZ (1) | NZ751836A (enExample) |
| WO (1) | WO2018049401A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3595681A4 (en) * | 2017-03-16 | 2020-12-16 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | TRANSPLANT CELL-BASED IMMUNOTHERAPY FOR LONG-PERIOD ADMINISTRATION OF THERAPEUTIC PROTEIN |
| WO2021108650A1 (en) * | 2019-11-27 | 2021-06-03 | Board Of Regents, The University Of Texas System | Large-scale combined car transduction and crispr gene editing of b cells |
| WO2023283585A2 (en) * | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| US20240352420A1 (en) * | 2021-07-29 | 2024-10-24 | Regents Of The University Of Minnesota | Multiplex base editing of primary human natural killer cells |
| WO2024015925A2 (en) * | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024196669A2 (en) * | 2023-03-17 | 2024-09-26 | Walking Fish Therapeutics, Inc. | Methods for in vivo editing of b cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2965224A1 (en) * | 2014-10-24 | 2016-04-28 | Bcrt Holding Bv | T cell-based immunotherapeutics |
| EP4177336A1 (en) * | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| CA2981077A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
-
2017
- 2017-09-12 US US16/332,555 patent/US20220168342A1/en active Pending
- 2017-09-12 AU AU2017322733A patent/AU2017322733B2/en active Active
- 2017-09-12 CA CA3036820A patent/CA3036820A1/en active Pending
- 2017-09-12 EP EP17849776.4A patent/EP3509606A4/en active Pending
- 2017-09-12 JP JP2019513999A patent/JP2019526270A/ja not_active Withdrawn
- 2017-09-12 NZ NZ751836A patent/NZ751836A/en unknown
- 2017-09-12 WO PCT/US2017/051182 patent/WO2018049401A1/en not_active Ceased
- 2017-09-12 CN CN201780059655.8A patent/CN109843303A/zh active Pending
-
2022
- 2022-10-07 JP JP2022162584A patent/JP2022189863A/ja active Pending
-
2025
- 2025-10-10 JP JP2025171949A patent/JP2025188209A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015112626A8 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
| MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
| CY1123028T1 (el) | Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf | |
| UA114108C2 (uk) | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання | |
| CA3045233A1 (en) | Novel t cell receptors and immune therapy using the same | |
| JP2010227108A5 (enExample) | ||
| BR112018074325A2 (pt) | anticorpo para ligação a receptor de interleucina 4 | |
| MX2022000012A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
| CL2013001124A1 (es) | Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo. | |
| CN109790222A (zh) | 抗密蛋白18a2的抗体及其应用 | |
| JP2011155981A5 (enExample) | ||
| EA201491171A1 (ru) | Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения | |
| WO2018104909A3 (en) | Dna methylation profiling for t-cell immunotherapy | |
| BR112013018311A2 (pt) | sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada. | |
| BR112017014031A2 (pt) | n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado. | |
| EA202091166A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
| JP2016510594A5 (enExample) | ||
| JP2011152135A5 (enExample) | ||
| EA201370076A1 (ru) | Иммуноглобулины-переносчики и их применение | |
| JP2013539454A5 (enExample) | ||
| FI3792628T3 (fi) | Menetelmiä neoantigeenien hyödyllisyyden ennustamiseen immunoterapiassa | |
| WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
| JP2017501211A5 (enExample) | ||
| JP2018023397A5 (enExample) | ||
| EP4353256A3 (en) | Induction of cross-reactive cellular response against rhinovirus antigens |